- WKN: 663720
- ISIN: DE0006637200
- Land: Deutschland
Nachricht vom 30.03.2012 | 07:46
MOLOGEN AG: Treatment with renal cancer therapy MGN1601 generates clear survival benefit for patients
MOLOGEN AG / Key word(s): Study 30.03.2012 07:46 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement.
Ad-hoc-Announcement of 03/30/2012 MOLOGEN AG: Treatment with renal cancer therapy MGN1601 generates clear survival benefit for patients - First evaluation of survival times provides results that exceed expectations - Immunological active principle proven in an exemplary manner In a further evaluation of the phase I/II renal cancer study with MGN1601, the biotechnology company MOLOGEN AG has analyzed the survival times of patients enrolled in the study and the first data of the accompanying immunological tests. The result: patients that were able to completely finish the twelve-week therapy scheme scheduled in the study protocol with the study drug MGN1601 (PP group) have an unexpectedly clear survival benefit in comparison with patients that had to terminate their study therapy early (non-PP group). Thus far, the ten patients in the PP group already survived more than ten months on average. Since only one patient in this group has died by now, this parameter will continue to improve. In the non-PP group, the median survival time is a little over two months; all nine patients had died at the latest after six months. With regard to historical clinical data and statistical models, a median survival time of five to seven months was expected. Hence, this was clearly exceeded in this study. Furthermore it is very remarkable that for two patients who are currently being treated in the extension phase of the study at fixed intervals, the disease has not progressed in over ten months. Immunological principle proven in an exemplary manner With the evaluation of immunological data it was possible to prove in an exemplary manner that those patients that completed the entire planned three-month treatment cycle with MGN1601 in accordance with the study protocol have generated a clear immune response. The strength of the immune response increased with continued treatment. With these results, the mechanism of action demonstrated in preclinical studies could also be confirmed in patients. In the view of MOLOGEN AG, the observed positive effects with respect to overall survival can thus be attributed to the treatment with MGN1601.
Information and Explaination of the Issuer to this News: About MOLOGEN AG MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime Standard of the German stock exchange. Memberships in associations: Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI) MIDGE(R), dSLIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. MOLOGEN AG PRESS SERVICE: Prof. Peter W. Huebner Head of Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Tel: +49 - 30 - 84 17 88 - 50 firstname.lastname@example.org INVESTOR RELATIONS: Joerg Petrass Tel: +49 - 30 - 84 17 88 - 13 Tel: +49 - 30 - 84 17 88 - 50 email@example.com External Investor Relations: Kirchhoff Consult AG Sebastian Bucher T: +49 - 40 - 60 91 86 - 18 F: +49 - 40 - 60 91 86 -16 firstname.lastname@example.org Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation. 30.03.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: email@example.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service
MOLOGEN AG: First patient recruited in combina ...
MOLOGEN AG: Verlustanzeige nach §92 Absatz 1 A ...
MOLOGEN AG: Report of loss pursuant to section ...
MOLOGEN AG: Medium-term funding from existing ...
MOLOGEN AG: First patients enrolled in extensi ...
GBC im Fokus
Neovacs S.A.: Kurzfristige Potenziale durch Fast-Track-Zulassung möglich
Das in Frankreich ansässige Biotechnologieunternehmen Neovacs S.A. fokussiert sich auf die Entwicklung so genannter Kinoide, welche für die Behandlung von Autoimmunerkrankungen sowie entzündlichen Erkrankungen verwendet werden. Der Neovacs-Wirkstoff wird derzeit im Rahmen einer klinischen Studie IIb (SLE) in 19 Ländern (Europa, Asien, Lateinamerika, USA) an 178 Patienten untersucht. Wir rechnen mit den ersten Ergebnissen in Sommer 2017.
Im Rahmen des DCF-Bewertungsmodells haben wir inkl. eines hohen Sicherheitsabschlages einen fairen Wert von2,90 € je Aktie ermittelt. Wir vergeben das Rating KAUFEN.
Der AKTIONÄR News
28. Juli 11:55 Samsung: Die Luft für Apple wird dünner
28. Juli 11:51 Deutsche Bank: Der Alptraum geht weiter
28. Juli 11:20 Nach Fed-Entscheid - DAX testet 3-Monats-Hoch
News im Fokus
AD-HOC: adidas Konzern gibt vorläufige Geschäftsergebnisse bekannt und erhöht Prognose für 2016
28. Juli 2016, 08:26
Presentation of the interim results 2016
04. August 2016
Original-Research: Ludwig Beck AG (von GBC AG): Halten
27. Juli 2016